Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Gynecol Oncol. 2021 May;161(2):613-620. doi: 10.1016/j.ygyno.2021.02.024. Epub 2021 Mar 3.
Recent studies have revealed that circulating tumor cells (CTCs) might predict bad prognosis, but the results were conflicting. Sampling time, treatment, enrichment method and detection method also varied. We aimed to evaluate whether patients with CTCs in peripheral blood have bad survival outcomes with consideration of the above four aspects.
Relevant studies were searched on Pubmed, Embase and the Cochrane Library. Studies of CTCs involving survival data available were identified for a systematic review and meta-analysis. HRs and 95% CIs for PFS and OS were extracted directly or from the Kaplan-Meier survival curves by the Engauge Digitizer v4.1. Subgroup analyses were performed to evaluate the effect of sampling time, treatment, enrichment method and detection method.
Two clinical trials and thirteen retrospective studies with a total of 1285 patients were included. CTCs significantly correlated with OS (HR = 1.77, 95%CI:1.42-2.21, p < 0.00001 and PFS (HR = 1.53, 95%CI:1.26-1.86, p < 0.0001). Subgroup analyses showed that CTCs were significant associated with OS in the "Pre-therapy" subgroup (HR = 1.79, 95%CI:1.43-2.24, p < 0.00001), the "Surgery" group (HR = 1.82, 95%CI:1.42-2.33, p < 0.00001), and the "RT-PCR"subgroup (HR = 2.29, 95%CI:1.53-3.42, p < 0.0001). While for enrichment method, CTCs significantly correlated with OS in the"Physical method" subgroup (HR = 1.94, 95%CI:1.21-3.09, p = 0.006) and the "Immunological method" subgroup (HR = 1.84, 95%CI:1.37-2.48, p < 0.0001).
The presence of CTCs prior to the treatment indicated worse OS and PFS and CTCs might be predictive biomarker for ovarian cancer patients . CTCs detected using RT-PCR seem to be associated with poorer OS and PFS in patients with ovarian cancer.
最近的研究表明循环肿瘤细胞(CTC)可能预示着不良预后,但结果存在冲突。采样时间、治疗、富集方法和检测方法也有所不同。我们旨在评估在考虑上述四个方面的情况下,外周血中存在 CTC 的患者是否具有不良的生存结局。
在 Pubmed、Embase 和 Cochrane Library 上检索相关研究。对涉及生存数据的 CTC 研究进行系统评价和荟萃分析。通过 Engauge Digitizer v4.1 直接或从 Kaplan-Meier 生存曲线中提取 HRs 和 95%CI 用于 PFS 和 OS。进行亚组分析以评估采样时间、治疗、富集方法和检测方法的影响。
纳入了两项临床试验和十三项回顾性研究,共计 1285 名患者。CTC 与 OS(HR=1.77,95%CI:1.42-2.21,p<0.00001)和 PFS(HR=1.53,95%CI:1.26-1.86,p<0.0001)显著相关。亚组分析显示,在“治疗前”亚组(HR=1.79,95%CI:1.43-2.24,p<0.00001)、“手术”组(HR=1.82,95%CI:1.42-2.33,p<0.00001)和“RT-PCR”亚组(HR=2.29,95%CI:1.53-3.42,p<0.0001)中,CTC 与 OS 显著相关。而对于富集方法,在“物理方法”亚组(HR=1.94,95%CI:1.21-3.09,p=0.006)和“免疫方法”亚组(HR=1.84,95%CI:1.37-2.48,p<0.0001)中,CTC 与 OS 显著相关。
治疗前存在 CTC 表明 OS 和 PFS 更差,CTC 可能是卵巢癌患者的预测生物标志物。在卵巢癌患者中,使用 RT-PCR 检测到的 CTC 似乎与较差的 OS 和 PFS 相关。